A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This trial is an open-label, multicenter phase Ib/II clinical study to evaluate the efficacy and safety of LBL-024 monotherapy or in combination with albumin-bound paclitaxel in patients with recurrent or metastatic triple negative breast cancer(TNBC).
Phase:
PHASE1
Details
Lead Sponsor:
Nanjing Leads Biolabs Co.,Ltd
Collaborator:
The First Affiliated Hospital with Nanjing Medical University